Watson Pharmaceuticals (002907.SZ): ORIC-1327 phosphate eye drops approved for drug clinical trials

Zhitongcaijing · 2d ago

Zhitong Finance App News, Watson Pharmaceutical (002907.SZ) issued an announcement. The company's holding subsidiary, Chengdu Huasen Aorui Pharmaceutical Co., Ltd. (hereinafter referred to as “Watson Aorui”), recently received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for ORIC-1327 phosphate eye drops corresponding to 2 indications and 6 specifications.

ORIC-1327 phosphate eye drops (project number ORIP-1009) is a selective small molecule inhibitor independently developed by Watson Auray and has completely independent intellectual property rights. It is clinically intended for the treatment of patients with glaucoma and ocular hypertension. Preclinical studies have confirmed that the drug has significant intraocular pressure lowering effects in New Zealand rabbits and crab-eating monkeys, and also has good eye safety, showing good prospects for drug development.